{
    "2018-03-08": [
        [
            {
                "time": "2018-02-01",
                "original_text": "Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up",
                "features": {
                    "keywords": [
                        "Q4",
                        "Loss Narrows",
                        "Revenues Beat",
                        "Shares Up"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "Analyst Recommendations for Johnson & Johnson in February 2018",
                "features": {
                    "keywords": [
                        "Analyst Recommendations",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Label Expansion May Boost Xultophy’s Sales in 2018",
                "features": {
                    "keywords": [
                        "Label Expansion",
                        "Xultophy",
                        "Sales"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Analysts’ Estimates for Johnson & Johnson after 4Q17",
                "features": {
                    "keywords": [
                        "Analysts’ Estimates",
                        "Johnson & Johnson",
                        "4Q17"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Xultophy May Prove a Strong Growth Driver for NVO in 2018",
                "features": {
                    "keywords": [
                        "Xultophy",
                        "Growth Driver",
                        "NVO"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "What Analysts Recommend for Bristol-Myers Squibb",
                "features": {
                    "keywords": [
                        "Analysts Recommend",
                        "Bristol-Myers Squibb"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Merck to Pay $300M Upfront to Co-Develop Eisai's Cancer Drug",
                "features": {
                    "keywords": [
                        "Merck",
                        "$300M",
                        "Co-Develop",
                        "Eisai",
                        "Cancer Drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Lilly, Boehringer to Expand Jardiance Heart Failure Program",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Boehringer",
                        "Jardiance",
                        "Heart Failure Program"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-01",
                "original_text": "See what the IHS Markit Score report has to say about Eli Lilly And Co.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "Novo Nordisk Has Developed a Portfolio of New-Generation Insulins",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "New-Generation Insulins"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research",
                "features": {
                    "keywords": [
                        "EFSD",
                        "JDRF",
                        "Lilly",
                        "Type 1 Diabetes Research"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research",
                "features": {
                    "keywords": [
                        "EFSD",
                        "JDRF",
                        "Lilly",
                        "Type 1 Diabetes Research"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}